Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries

• US veterans and eligible family members now have access to blood test for colorectal cancer screening with no copay
• Benefit will cover all eligible individuals ages 45-84, representing first coverage beyond Medicare population for Shield

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now covered by a key healthcare insurance program for U.S. veterans. The screening test is covered for patients receiving community care authorized by the U.S. Department of Veterans Affairs (VA) as an in-network benefit, with no copay for average-risk individuals who are age 45 or older.

Following Medicare coverage for Shield in August 2024, the VA network coverage is the first for individuals between the ages of 45 and 64. The U.S. Department of Veterans Affairs (VA) Community Care Network (CCN) consists of community-based practitioners who provide veterans with healthcare services and covers approximately 9.1 million beneficiaries.¹

“We are proud of the lifesaving value that the Shield blood test can bring to U.S. veterans and their families,” said AmirAli Talasaz, Guardant Health co-CEO. “This coverage decision by the VA is the first for younger and non-Medicare beneficiaries and we are excited to broaden the impact of our screening test to help detect more colorectal cancer early, when it is most treatable.”

The U.S. Food and Drug Administration (FDA) approved Shield in July 2024 as the first blood test for primary CRC screening, and the Centers for Medicare & Medicaid Services (CMS) recently approved Advanced Diagnostic Laboratory Test (ADLT) status for Shield for colorectal cancer screening.

The Shield blood test is FDA approved for primary non-invasive screening for colorectal cancer in average-risk individuals age 45 and older and can be ordered by any prescribing healthcare provider. For more information, visit www.ShieldCancerScreen.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Guardant Health Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

References
1. https://www.data.va.gov/dataset/VetPop2023-State-Data-6L/f43c-vb9n/data_preview

View source version on businesswire.com: https://www.businesswire.com/news/home/20250325726184/en/

Investor Contact:

Zarak Khurshid

investors@guardanthealth.com

Media Contact:

Michael Weist

press@guardanthealth.com

+1 317-371-0035

Source: Guardant Health, Inc.